NasdaqGS:OLMABiotechs
A Look At Olema Pharmaceuticals (OLMA) Valuation After Earnings And New Shelf Registration Filing
Why Olema’s latest earnings and shelf filing matter for investors
Olema Pharmaceuticals (OLMA) has drawn fresh attention after reporting fourth quarter and full year 2025 results, along with a new shelf registration of up to US$71.82 million in common stock.
The company posted a fourth quarter net loss of US$46.06 million and a full year 2025 net loss of US$162.45 million. It also registered 4,882,586 shares for an ESOP related offering that could affect future dilution and funding...